TuHURA Biosciences and Kintara Therapeutics Announce Positive Results from Phase 1b Trial of IFx-2.0, a Novel Personalized Cancer Vaccine, in Checkpoint Inhibitor Resistant Advanced Merkel Cell Carcinoma (MCC) and Cutaneous Squamous Cell Carcinoma (cSCC)

June 3, 2024 8:35 AM

TuHURA's lead candidate, IFx-2.0, was safe and well tolerated at once weekly dosing for 3 weeksEighty percent (80%) of ICI naïve patients with advanced MCC who failed to respond to pembrolizumab or avelumab therapy achieved a durable Complete Response (CR), pathologic CR or Partial Response (PR) following IFx-2.0 therapy and rechallenge with an anti-PD(L)-1 checkpoint inhibitorData presented at the 2024 American Society of Clinical Oncology...

Read more

Alligator Bioscience's Phase 2 mitazalimab Pancreatic Cancer Data Published in The Lancet Oncology

June 3, 2024 2:20 AM

LUND, SE / ACCESSWIRE / June 03, 2024 / Alligator Bioscience (STO:ATORX)Publication in world-leading clinical oncology journal validates the quality and potential implications of Phase 2 OPTIMIZE-1 resultsThe study reported Objective Response Rate (ORR) of 40.4% in 57 evaluable patients, primary endpoint was met.The novel combination of mitazalimab and mFOLFIRINOX and the unique dosing schedule resulted in an unprecedented Duration of Response...

Read more

Helius Medical Technologies, Inc. to Present at the Spring MicroCap Rodeo Conference

May 31, 2024 12:30 PM

NEWTOWN, PA / ACCESSWIRE / May 31, 2024 / Helius Medical Technologies, Inc., (Nasdaq:HSDT) ("Helius" or the "Company"), a neurotech company focused on delivering a novel therapeutic neuromodulation approach for balance and gait deficits, today announced that it will participate in the Spring MicroCap Rodeo Conference to be held on Thursday, June 6th in NYC.Dane Andreeff, CEO, will attend the conference and plans to discuss:Pursuit of a stroke...

Read more

InnoSIGN Launches New Suite Products for Pharmaceutical Research and Clinical Studies

May 31, 2024 9:00 AM

Analysis of aberrant pathway signaling provides the greatest insight into targeted therapiesMASON, OH and EINDHOVEN, THE NETHERLANDS / ACCESSWIRE / May 31, 2024 / InnoSIGN, a life sciences company committed to advancing precision medicine through a proprietary, innovative platform that identifies the true drivers of disease, today announced that it has launched a suite of products and services with this platform directed at supporting...

Read more

Increase of Number of Shares and Votes in Vicore Pharma

May 31, 2024 3:20 AM

STOCKHOLM, SE / ACCESSWIRE / May 31, 2024 / Vicore Pharma Holding (STO:VICO) Stockholm, May 31, 2024 - Vicore Pharma Holding AB (STO: VICO) ("Vicore") announced today that the number of Vicore shares and votes has increased following the exercise of warrants with subsequent delivery of shares to a participant in the incentive program Board LTIP 2023. The shares were issued through the exercise of 11,025 share rights, which are entitled to an...

Read more

New Research Study Reveals Critical Role of Magnesium in Regulating Brain Synapses and Cognition

May 30, 2024 12:00 PM

High Levels of Intracellular Magnesium Promote a Large Number of Weak Synaptic Configurations, Optimal for Encoding New Information and LearningWALNUT CREEK, CA. / ACCESSWIRE / May 30, 2024 / Neurocentria Inc., a privately held late-stage biotechnology company developing novel therapies for Alzheimer's disease, Attention Deficit Hyperactivity Disorder (ADHD), Major Depressive Disorder (MDD) and other neurodegenerative and neuropsychiatric...

Read more

BioInvent to Host Virtual KOL Event to Highlight Recently Presented Efficacy Data from BioInvent's Lead Candidates BI-1808 and BI-1206

May 30, 2024 8:30 AM

BioInvent International (STO:BINV) Discussion on TNFR2 and FcyRIIB as promising targets in immuno-oncology on June 18, 2024LUND, SWEDEN / ACCESSWIRE / May 30, 2024 / BioInvent International AB ("BioInvent") (Nasdaq Stockholm:BINV), a biotech company focused on the discovery and development of novel and first-in-class immune-modulatory antibodies for cancer immunotherapy, today announced that it will host a virtual KOL event on Tuesday, June 18,...

Read more

FluoGuide A/S Publishes Interim Report for the Period January - March 2024

May 30, 2024 3:05 AM

KØBENHAVN, DK / ACCESSWIRE / May 30, 2024 / FluoGuide A/S (STO:FLUO) Copenhagen, Denmark, 30 May 2024 - FluoGuide A/S ("FluoGuide" or the "Company") today releases its results for the period 1 January - 31 March 2024. The Q1 report is available as an attached document to this press release and on FluoGuide's website.FluoGuide had no revenue for the period and posted a net loss of DKK 7,521 thousand (DKK 9,535 thousand) for the period 1 January...

Read more

DiviTum(R) TKa Results to be Presented at ASCO the World’s Largest Cancer Conference

May 30, 2024 2:50 AM

UPPSALA, SWEDEN / ACCESSWIRE / May 30, 2024 / Biovica International (STO:BIOVIC-B)(STO:BIOVIC.B)(FRA:9II) Biovica, active in cancer diagnostics, today announces that results with DiviTum® TKa from the Spanish GEICAM/2014-12 FLIPPER trial will be presented at the world's largest cancer conference, the annual ASCO meeting on June 2, 2024 9:00 AM - 12:00 PM CDT. The data supports the use of DiviTum TKa to predict outcome and progression on first...

Read more

Petros Pharmaceuticals Successfully Completes AI-Integrated Formative Human Factors Study Demonstrating Positive Interaction with Web App Designed for STENDRA(R) (avanafil) OTC Switch

May 29, 2024 9:00 AM

Petros Pharmaceuticals, Inc. (NASDAQ:PTPI) ("Petros" or the "Company"), a company focused on expanding consumer access to medication through over-the-counter ("OTC") drug development programs, announces the successful completion of a Formative Human Factors study of its AI-integrated Web App, designed to facilitate OTC access of STENDRA® (avanafil) for consumers. This important development follows the Company's recent execution of an AI...

Read more

Tharimmune to Present at 2024 BIO International Convention

May 29, 2024 8:30 AM

BRIDGEWATER, NJ / ACCESSWIRE / May 29, 2024 / Tharimmune, Inc. (NASDAQ:THAR) ("Tharimmune" or the "Company"), a clinical-stage biotechnology company developing a portfolio of therapeutic candidates in inflammation and immunology, announces that management will be presenting at the 2024 BIO International Convention being held June 3-6, 2024 in San Diego.The Company will be presenting at the convention and will hold 1x1 meetings with investors and...

Read more

Indica Labs Announces AI-Powered HALO(R) Software Release for Digital Pathology Research in Life Sciences

May 29, 2024 8:00 AM

Indica Labs, the global leader in AI-powered digital pathology solutions, announced today the release of the transformative new version of its industry leading life sciences software. The 4.0 versions of HALO®, HALO AI, and HALO Link offer researchers and pathologists unparalleled ease of use and performance, with even more opportunities to leverage advanced AI-powered image analysis in an open digital pathology ecosystem. The proliferation...

Read more

New Study Quantifies the Impact of Improved Clinical Trial Design Using Faro Health's Study Designer Tool

May 29, 2024 7:00 AM

Digital tool gives real-time feedback on the impact of changes to clinical study protocols, helping clinical teams reduce the cost, duration and burden of studies on sponsors, sites and patients.SAN DIEGO, CA / ACCESSWIRE / May 29, 2024 / A new study, published in the peer-reviewed journal Therapeutic Innovation & Regulatory Science and conducted in collaboration with Merck, shows that when Faro's Study Designer Tool was applied to clinical...

Read more

RNAConnect Launches UltraMarathonRT(TM), an Ultra-Processive Next-Generation Reverse Transcriptase

May 28, 2024 9:00 AM

BRANFORD, CT / ACCESSWIRE / May 28, 2024 / RNAConnect, a pioneering life science tools company, officially announced the commercial launch of UltraMarathonRT™ (uMRT), a next-generation, ultra-processive reverse transcriptase. Available as part of a Reverse Transcriptase Kit and a Template Switching Kit, uMRT is a highly engineered RT that overcomes the limitations of existing reverse transcriptases by creating full-length cDNAs from any RNA...

Read more

Ensysce Biosciences Regains Compliance with Nasdaq

May 28, 2024 8:00 AM

Ensysce Biosciences, Inc. (NASDAQ:ENSC) ("Ensysce" or the "Company"), a clinical stage pharmaceutical company developing innovative solutions for severe pain relief while reducing the potential for opioid abuse and overdose, today announced that it has received notice on May 24, 2024 from The Nasdaq Stock Market LLC ("Nasdaq") that the Company has demonstrated compliance with the equity requirement in Listing Rule 5550(b)(1), as described in the...

Read more

Imagene Advances LungOI Commercialization With New Payment Code and Pricing, Complementing Its Prior CLIA Certified US Lab

May 28, 2024 8:00 AM

LungOI Is Among The First AI-based Tests To Receive a Medicare Payment Rate.MIAMI, FL / ACCESSWIRE / May 28, 2024 / Imagene, a pioneer in AI-based precision oncology, is pleased to announce the culmination of key milestones in the commercialization of its AI-based NSCLC Biomarker Profiling Test, LungOITM. Earlier this year, Imagene secured a novel payment code and payment rate from the Centers for Medicare and Medicaid Services (CMS). LungOI -...

Read more

Ondine Biomedical Inc Announces Notice of Results, Investor Presentation, and AGM

May 28, 2024 2:00 AM

Ondine Biomedical Inc. (AIM:OBI) announces that it will publish its audited results for the year ended 31 December 2023 ("Full Year Results") and Annual Report 2023 on 7 June 2024. Dr. Nicolas Loebel, President and Chief Technology Officer of the Company, will provide a live presentation relating to the Full Year Results via Investor Meet Company on 10 June 2024, 16:30 BST (08:30 Pacific time).The presentation is open to all existing and...

Read more

FluoGuide Selects Laser System for Photothermal Cancer Therapy with FG001

May 27, 2024 4:00 AM

FluoGuide A/S (STO:FLUO) Copenhagen, Denmark - FluoGuide A/S ("FluoGuide" or the "Company"), a biotech company specializing in precision cancer surgery, has chosen laser system for the development of photothermal therapy (PTT).FluoGuide's lead product, FG001 fluoresces and is designed to bind urokinase-type plasminogen activator receptor (uPAR) making it specific to cancer and with a potential for most patients with solid cancer. Clinical data...

Read more

BioInvent to Host Virtual KOL Event on June 18, 2024, to Discuss BioInvent's Lead Candidates BI-1808 and BI-1206

May 24, 2024 9:15 AM

LUND, SWEDEN / ACCESSWIRE / May 24, 2024 / BioInvent International (STO:BINV) TNFR2 and FcyRIIB are promising targets in immuno-oncology.BioInvent International AB ("BioInvent") (Nasdaq Stockholm:BINV), a biotech company focused on the discovery and development of novel and first-in-class immune-modulatory antibodies for cancer immunotherapy, today announced that it will host a virtual KOL event on Tuesday, June 18, 2024 from 9:00-10:45 AM...

Read more

ASP Isotopes and Calidi Biotherapeutics Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

May 24, 2024 9:00 AM

ORLANDO, FL / ACCESSWIRE / May 24, 2024 / RedChip Companies will air interviews with ASP Isotopes Inc. (Nasdaq:ASPI) and Calidi Biotherapeutics Inc. (NYSE American:CLDI) on the RedChip Small Stocks, Big Money™ show, a sponsored program on Bloomberg TV, this Saturday, May 25, at 7 p.m. Eastern Time (ET). Bloomberg TV is available in an estimated 73 million homes across the U.S.Access the interviews in their entirety at:ASP Isotopes:...

Read more